Complexity of FGFR signalling in metastatic urothelial cancer.

ABSTRACT:

Background

Urothelial cancers (UC) are the fourth most common tumours worldwide after prostate (or breast), lung and colorectal cancer. Despite recent improvements in their management, UC remain an aggressive disease associated with a poor outcome. Following disease progression on first-line platinum-based chemotherapy, very few effective treatment options are available and none of them have shown significant improvement in overall survival. Alterations of the fibroblast growth factor receptor (FGFR) pathway including amplification, mutations and overexpression are common in UC. Pre-clinical data suggest that the presence of such dysregulations may confer sensitivity to FGFR inhibitors.

Materials and methods

We present here the case of a patient with a metastatic UC of the r

SUBMITTER: Rodriguez-Vida A 

PROVIDER: S-EPMC4619431 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature